Syndax Pharmaceuticals Inc.

12 days ago · seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

18 days ago · globenewswire.com

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

21 days ago · globenewswire.com

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.

2 months ago · seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease therapy Niktimvo continued to grow.

2 months ago · zacks.com

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.

2 months ago · globenewswire.com

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3 million in 2Q26, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million – – Expanded pipeline with a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC and an internally developed next-generation menin inhibitor for myelofibrosis – – Topline data expected in 4Q26 from Phase 2 trials of axatilimab in IPF and frontline cGVHD – – Company to host a conference call today at 4:30 p.m. ET – NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today reported its financial results for the second quarter ended June 30, 2026, and provided a business update.

2 months ago · globenewswire.com

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2026 financial results and provide a business update on Tuesday, August 4, 2026.

2 months ago · zacks.com

Does Syndax Pharmaceuticals (SNDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago · seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies Transcript